Contents 3 min read

Claim and source comparison

Comparison scope: PubMed abstracts of Llewellyn 2010, VITAL-DEP 2020 and VITAL cognition 2021; NIH ODS sections on metabolites, testing, intake and safety. Not full-text or independent clinical review of all sources.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human observational study

Llewellyn 2010: In 858 adults aged 65+, low 25(OH)D was associated with cognitive decline over six years. Adjusted relative risk for MMSE decline comparing <25 with ≥75 nmol/L was 1.60 (95% CI 1.19–2.00).

An observational cohort is not a supplementation trial; it proves neither causality nor dementia prevention with D3. Comparison thresholds are not universal clinical targets.

Source 4 · Abstract read

Human randomized controlled trial

VITAL-DEP 2020: In 18,353 adults without clinically relevant depressive symptoms at baseline, 2000 IU/day D3 did not significantly reduce depression/relevant symptom risk versus placebo over a median 5.3 years: HR 0.97 (95% CI 0.87–1.09). Mood scores also showed no benefit.

A prevention trial does not test active depression treatment or selected severe-deficiency patients. Its dose is not a personal prescription; associations do not establish preventive benefit.

Source 7 · Abstract read

Human randomized controlled trial

VITAL 2021: 3424 adults aged 60+ were assessed by phone and 794 in person. D3 2000 IU/day did not significantly slow global cognitive decline over 2–3 years: annual difference 0.01 (95% CI −0.01–0.02; p=0.39).

A subgroup signal among Black participants needs confirmation and is distinct from the overall null finding. Limited follow-up does not definitively assess every deficiency group or lifetime dementia risk.

Source 8 · Abstract read

Official safety summary

NIH ODS reports a circulating half-life of about 15 days for 25(OH)D, a D3 metabolite and status marker. Circulating calcitriol has a half-life measured in hours.

Metabolite duration does not define a one-compartment oral D3 decay curve or personal redosing time. The valid 15-day information is retained without a D3 elimination model.

Source 5 · Official summary read

Official safety summary

NIH ODS notes that excessive vitamin D can cause hypercalcemia and kidney damage; thiazides may increase hypercalcemia risk. Routine 25(OH)D testing is not recommended for all healthy people; testing and deficiency treatment depend on clinical context. Do not independently change treatment.

Total daily intake, upper limit and deficiency treatment are distinct concepts. Official guidance is not a personal dose or screening plan; missing interaction records are not safety evidence.

Source 5 · Official summary read

Our evidence and source methodology

Vitamin D3: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Vitamin D3?

Vitamin D3 is important for bone and calcium metabolism; treating deficiency depends on medical assessment. Associations of low levels with depression or cognitive decline do not establish that supplements prevent or treat these conditions.

Vitamin D3 (cholecalciferol) is a fat-soluble vitamin synthesized when UVB radiation in sunlight converts skin cholesterol. It is converted to 25-hydroxyvitamin D3 (25-OH-D3) in the liver and then to the active form 1,25-dihydroxyvitamin D3 (calcitriol) in the kidney. Calcitriol in the cell nucleus Vitamin D receptors (VDR) binds and regulates gene expression.

Clinical Trials

Llewellyn 2010: In 858 adults aged 65+, low 25(OH)D was associated with cognitive decline over six years. Adjusted relative risk for MMSE decline comparing <25 with ≥75 nmol/L was 1.60 (95% CI 1.19–2.00).

An observational cohort is not a supplementation trial; it proves neither causality nor dementia prevention with D3. Comparison thresholds are not universal clinical targets.

VITAL-DEP 2020: In 18,353 adults without clinically relevant depressive symptoms at baseline, 2000 IU/day D3 did not significantly reduce depression/relevant symptom risk versus placebo over a median 5.3 years: HR 0.97 (95% CI 0.87–1.09). Mood scores also showed no benefit.

A prevention trial does not test active depression treatment or selected severe-deficiency patients. Its dose is not a personal prescription; associations do not establish preventive benefit.

VITAL 2021: 3424 adults aged 60+ were assessed by phone and 794 in person. D3 2000 IU/day did not significantly slow global cognitive decline over 2–3 years: annual difference 0.01 (95% CI −0.01–0.02; p=0.39).

A subgroup signal among Black participants needs confirmation and is distinct from the overall null finding. Limited follow-up does not definitively assess every deficiency group or lifetime dementia risk.

Dose information and research limits

⚠ Research Limitations

Under NIH/FNB criteria, 25(OH)D ≥50 nmol/L is adequate for most people; 50–75 nmol/L is not a universal deficiency range. Recommended total adult intake is 600 IU/day, or 800 IU above age 70; 4000 IU/day is an upper limit, not a target. Deficiency treatment and testing need individualized assessment.

NIH ODS reports a circulating half-life of about 15 days for 25(OH)D, a D3 metabolite and status marker. Circulating calcitriol has a half-life measured in hours.

Metabolite duration does not define a one-compartment oral D3 decay curve or personal redosing time. The valid 15-day information is retained without a D3 elimination model.

Safety and Side Effects

NIH ODS notes that excessive vitamin D can cause hypercalcemia and kidney damage; thiazides may increase hypercalcemia risk. Routine 25(OH)D testing is not recommended for all healthy people; testing and deficiency treatment depend on clinical context. Do not independently change treatment.

Total daily intake, upper limit and deficiency treatment are distinct concepts. Official guidance is not a personal dose or screening plan; missing interaction records are not safety evidence.

K2 has not been established as mandatory with D3 for everyone or as prevention of vitamin D toxicity. Excess D3 can cause hypercalcemia and kidney injury; adding K2 does not make an overdose safe. Vitamin K can alter warfarin’s effect.

Vitamin D Deficiency in Türkiye

Vitamin D levels in Türkiye vary by age, region, season and study sample. A deficiency percentage from a clinical sample cannot be generalized to the population; a universal claim above 70% is not established.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Holick MF. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281. PubMed · PMID 17634462
  2. Shaffer JA, et al. (2014). Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine, 76(3), 190–196. PubMed · PMID 24632894
  3. Eyles DW, et al. (2013). Vitamin D effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Frontiers in Neuroendocrinology, 34(1), 47–64. PubMed · PMID 22796576
  4. Llewellyn DJ, et al. (2010). Vitamin D and risk of cognitive decline in elderly persons. Archives of Internal Medicine, 170(13), 1135–1141. PubMed · PMID 20625021
  5. NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ NIH Office of Dietary Supplements
  6. NIH Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/ NIH Office of Dietary Supplements
  7. Okereke OI, et al. (2020). Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA, 324(5), 471-480. https://doi.org/10.1001/jama.2020.10224 PubMed · PMID 32749491
  8. Kang JH, et al. (2021). Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. Scientific reports, 11(1), 23253. https://doi.org/10.1038/s41598-021-02485-8 PubMed · PMID 34853363

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions